Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
7
×
boston blog main
fda
7
×
life sciences
national blog main
national top stories
new york blog main
7
×
new york top stories
boston top stories
clinical trials
san diego blog main
san diego top stories
rna interference
san francisco blog main
san francisco top stories
deals
akcea therapeutics
biotech
boston
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
inotersen
national
novartis
patisiran
raleigh-durham blog main
raleigh-durham top stories
regeneron pharmaceuticals
sanofi
seattle blog main
seattle top stories
tafamidis
texas blog main
texas top stories
wisconsin blog main
What
fda
drug
alnylam
bio
medicine
roundup
deal
gene
help
medicines
patients
rna
rnai
uses
acquire
acquisitions
afternoon
ago
agreed
alnylam’s
alzheimer’s
announced
approve
approved
approves
aren’t
awaits
billion
biological
brings
cash
cells
ceo
cholesterol
collabs
company
compound
congress
covid
crossed
Language
unset
Current search:
fda
×
" alnylam pharmaceuticals "
×
" new york blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision